Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Nature Medicine (2)
Leukemia (1)
Nature Communications (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (3)
Amendments and Corrections (1)

Subject Check one or more subjects to show results from those subjects only.

Cancer
Immunology
Medical research
Oncology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–4 of 4 results

Advanced filters: Author: Lena Osswald Clear advanced filters

Strong constitutive NF-κB signaling in B cells drives SLL/CLL-like lymphomagenesis and overcomes microenvironmental dependencies

Valeria Soberón
Lena Osswald
Marc Schmidt-Supprian
ResearchOpen Access16 Jan 2026
Leukemia

P: 1-18
Oncogenic Kras^G12D causes myeloproliferation via NLRP3 inflammasome activation

Oncogenic Ras mutations are common drivers in myeloid leukemia. Here, the authors show in patient cells and in mice that oncogenic K-Ras activates NLRP3 inflammasome to drive myeloproliferation, which can be reversed by genetic or pharmacologic NLRP3 blockade.

Shaima’a Hamarsheh
Lena Osswald
Robert Zeiser
ResearchOpen Access03 Apr 2020
Nature Communications

Volume: 11, P: 1-17
Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Nimitha R Mathew
Francis Baumgartner
Robert Zeiser
Amendments and Corrections01 Apr 2018
Nature Medicine

Volume: 24, P: 526
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Combining the kinase inhibitor sorafenib with allogeneic stem cell transplantation boosts immune responses against a subtype of acute myelogenous leukemia, suggesting potential clinical benefit.

Nimitha R Mathew
Francis Baumgartner
Robert Zeiser
Research12 Feb 2018
Nature Medicine

Volume: 24, P: 282-291